Public consultation on cancer medicines
EMA Highlights by Gary Finnegan – The EMA has launched a public consultation on its revised guidelines covering how potential cancer drugs are assessed. The document provides guidance… read more.
EMA Highlights by Gary Finnegan – The EMA has launched a public consultation on its revised guidelines covering how potential cancer drugs are assessed. The document provides guidance… read more.
Researchers from the University of Southampton, in collaboration with psychologists from six other universities, have started a study to assess the impact of a new psychological therapy for… read more.
Brief adherence programmes improve diabetes test results and depression symptoms. Patients simultaneously treated for both Type 2 diabetes and depression showed improved medication compliance and significantly improved blood… read more.
It is estimated that there are 2.9 million people in the UK diagnosed with diabetes1 and the incidence is increasing, as it is across the world, all the… read more.
by Dr. Riyaz Shah, Consultant Medical Oncologist, Kent Oncology Centre – The ASCO 2011 Annual Meeting took place in early June at the vast McCormick Place Convention Centre… read more.
First study of its kind to focus on children. Crowding in hospital emergency departments has led to a decrease in the timely and effective use of pain medication… read more.
Up to one-third of cancer patients experience moderate to severe pain.
by Dr Sunil Upadhyay – Malignant Pleural Mesothelioma (MPM) is of insidious onset and almost uniformly a fatal disease. Around 90% of the patients can be linked to… read more.
by Dr Sunil Upadhyay – Advanced non-small cell carcinoma of the lung represents one of the major unmet needs for an effective and prolonged survival outcome. The majority… read more.
by Dr Sunil Upadhyay – Since the publication of the iPASS trial data, gefitinib has become the treatment of choice in EGFR mutation positive tumours. However, almost all… read more.
Foreward by Dr Sanjay Popat (pictured). The 14th Annual Scientific Meeting of the IASLC has now closed. Held in Amsterdam at the beginning of July 2011, the annual… read more.
Nephrotoxicity as the Primary Driver of Failure – Fact or Fiction? – Dr Philip Halloran, Alberta Applied Genomics Center, Alberta, Canada. The calcineurin inhibitors (CNIs), ciclosporin and tacrolimus,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.